Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine

Drug Metabolism and Disposition

Volumn 30, Issue 5, 2002, Pages 595-601

  Marcucci, Kenda A ^a   Pearce, Robin E ^a   Crespi, Charles ^b   Steimel, Dorothy T ^b   Steven Leeder, J ^a   Gaedigk, Andrea ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Gentest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6.1; CYTOCHROME P450 2D6.17; CYTOCHROME P450 2D6.2; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BACULOVIRUS; BINDING AFFINITY; CELL STRAIN COS7; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME SPECIFICITY; GENE EXPRESSION SYSTEM; GENETIC TRANSFECTION; IN VITRO STUDY; INSECT CELL; MICHAELIS CONSTANT; MICROSOME; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; DEXTROMETHORPHAN; ETHANOLAMINES; INSECTS; KINETICS; PHENOTYPE; SUBSTRATE SPECIFICITY; TRANSFECTION; VARIATION (GENETICS);

ANIMALIA; INSECTA; MAMMALIA; TRICHOPLUSIA NI; UNIDENTIFIED BACULOVIRUS;

EID: 0036233696     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.5.595     Document Type: Article

References (31)

1. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine
2. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
3. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: A review and preliminary data
4. The use of 3-[2-(N, N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes
5. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians
6. Optimization of cytochrome P450 2D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data
7. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population
8. Structure and function of cytochromes P450: A comparative analysis of three crystal structures
9. Metoprolol metabolism via CYP2D6 in ethnic populations
10. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences
11. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians
12. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans
13. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
14. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs
15. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: Association with diminished debrisoquine hydroxylase activity
16. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding
17. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients-relationship to the debrisoquine hydroxylation metabolic ratio
18. A combination of mutations in the CYP2D6*17(CYP2D6Z) allele causes alterations in enzyme function
19. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
20. CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: Evidence for an allelic variant with altered catalytic activity
21. Debrisoquine and metoprolol oxidation in Zambians: A population study
22. The relationship between paroxetine and the sparteine oxidation polymorphism
23. Non-correlations between debrisoquine and metoprolol polymorphisms in the Venda
24. Racial differences in propranolol enantiomer kinetics following simultaneous IV and oral administration
25. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
26. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity
27. Decreased capacity for debrisoquine metabolism among black Tanzanians: Analyses of the CYP2D6 genotype and phenotype
28. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians
29. Relationship of paroxetine disposition to metoprolol metabolite ratio and CYP2D610 genotype of Korean subjects
30. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
31. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6